Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine (NCT03108469), a randomized phase 2 study. The primary outcome is Migraine Days.

2. Clinical Question

3. Trial Design

This was a phase 2, randomized, double-blind, placebo-controlled, parallel-group study of IONIS-PKKRx (ISIS 546254) for preventive treatment of chronic migraine. The registry lists enrollment of 30 and a completed study. The listed start was 2017-08-01 and primary completion was 2019-04-26. These dates describe the registry record; they do not establish when every participant entered or completed treatment.

Participants were assigned to IONIS-PKKRx or placebo. The intervention descriptions specify subcutaneous injections containing 1.00 mL (200mg) weekly for weeks 1-16 in both groups. The record calls the study double-blind, but does not report which people involved in the trial were masked or how masking was maintained. Allocation concealment procedures are not reported in the registry record.

The design’s central comparison is between randomized groups, with the primary measure framed as change from baseline in migraine days through the final month of the 4-month treatment period. Randomization is intended, in general, to make treatment groups comparable on average at the point of assignment. Blinding can reduce the influence of expectations on care and reporting. Those design features do not by themselves establish that the analysis was unbiased: the analysis population, handling of missing observations, and specific statistical model are not reported in the registry record.

The record describes secondary outcomes covering headache severity and days, migraine medication use, a reduction threshold for migraine headaches, quality of life, and global impressions of change. It lists eight outcome measures, but gives no analysis results in this summary. The specific schedule and statistical handling for those secondary measures are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Migraine Days, measured over Comparing baseline to treatment period, up to 16 weeks.

The primary endpoint is migraine days, expressed as a mean continuous measure in days. The registry describes comparing baseline with the treatment period up to 16 weeks and specifies a comparison of monthly migraine days at baseline with the final month of the 4-month treatment period. The endpoint is intended to summarize how frequently migraine days occur over the specified observation periods, rather than focusing on a single episode or a yes-or-no response.

In general, a continuous endpoint can retain more gradation than a binary outcome because it distinguishes different observed values rather than grouping participants into categories. Comparing a follow-up measure with baseline can describe change over time, while comparing randomized groups can help distinguish the pattern in the intervention group from the pattern under placebo. These are general reasons such endpoints are used; they do not establish that a particular analysis was performed.

The registry identifies the summary parameter as a mean and the dispersion as a standard error. A standard error describes uncertainty around an estimated mean, not the spread of individual participants’ values. The record does not provide the actual group means, standard errors, between-group estimate, confidence interval, or a test result for this endpoint. It also does not provide enough detail to determine whether the primary comparison used change scores, an adjusted model, or another analysis approach. The posted endpoint description therefore defines the question, but the registry information does not quantify its answer.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry identifies the primary outcome as a mean of a continuous measure, with standard error as the dispersion summary. It does not specify the statistical model, test, analysis population, covariate adjustment, or missing-data method. The explanations below describe general statistical concepts relevant to this kind of endpoint; they are not claims about methods used in this study.

What does a mean represent?

In general, a mean summarizes the observed values by their average. For a migraine-days endpoint, the mean can describe the group’s average number of days over the relevant measurement period. A mean is easy to interpret as a group summary, but it does not describe the full distribution: participants can differ substantially even when the group mean is similar. Individual values, distributions, and the number of observed participants can help contextualize a mean, but those details are not reported in the registry record.

What does the standard error describe?

In general, a standard error describes the precision of an estimated mean under the analysis assumptions. It is not the same as a standard deviation, which describes variation among observations. A confidence interval is commonly formed using an estimate and its standard error, together with a method that reflects the analysis assumptions. The interval communicates uncertainty around an estimate; a narrower interval indicates greater precision under that method. The registry record names standard error but gives no value, confidence interval, or method for deriving one.

Why compare randomized groups?

In general, a randomized comparison is designed to estimate the difference between assignment groups while reducing systematic baseline differences on average. A treatment-versus-placebo contrast is more informative than interpreting change in the intervention group alone, since the placebo group can reflect time trends, expectations, and other influences that may affect both groups. This rationale depends on implementation and analysis. The registry labels the allocation randomized, but details about the randomization sequence and concealment are not reported in the registry record.

How does the baseline comparison fit?

The endpoint description compares baseline with the final month of treatment. In general, there are several possible ways to analyze repeated or baseline and follow-up measurements. An analysis may compare change from baseline between groups, compare follow-up values with baseline adjustment, or use a model that accounts for repeated observations. These approaches can differ in assumptions and precision. The registry description does not identify which approach was used, so it would be inappropriate to attribute a particular model or adjustment to the trial.

What is the role of a hypothesis test?

In general, a hypothesis test evaluates how compatible observed data are with a specified null model, under the test’s assumptions. A p-value is not the probability that the null hypothesis is true, and it does not measure the size or clinical importance of an effect. A test result is most informative alongside an effect estimate and confidence interval. The registry record does not report a primary p-value or effect estimate, so there is no test result to interpret.

Why can over-dispersion matter?

In general, count outcomes can vary more than a simple statistical model assumes. This is called over-dispersion. If the analysis assumes less variability than is present, standard errors may be too small and uncertainty may be understated. Methods designed for counts or models that allow extra variation can address this issue, depending on the endpoint and data structure. This is general context only: the registry record does not report whether a count model was considered, whether over-dispersion was assessed, or whether any specific model was used.

How should planning illustrations be read?

The sample-size section on the page is described as a planning illustration based on an observed effect, with a two-sided significance level of 0.05, equal allocation, and a normal approximation. The stated fraction of the observed effect defines the effect targeted in each illustration. In general, such calculations describe the sample size associated with specified assumptions; they do not establish the design assumptions that investigators used, and they are not observed power. The registry record does not report a sample-size justification or say that these calculations formed part of the original trial design. The illustration should therefore be read as a separate planning aid, not as a trial result.

The registry record does not report interim analyses, a statistical analysis plan, or a prespecified hierarchy for the outcomes. No particular method for controlling false-positive findings across multiple endpoints can be inferred from the outcome list alone.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists a primary endpoint described across several categories or time points, and the posted primary outcome was not reduced to one comparison. It also lists multiple secondary outcomes. When many outcomes, time points, or comparisons are examined, the chance of at least one apparently unusual result can increase. In general, a prespecified testing hierarchy or multiplicity adjustment can help govern interpretation, but the registry record does not report whether either was used. No adjustment method or prespecified order of testing is reported in the registry record.

The record does not report a statistical analysis plan, the definition of the analysis population, or whether analyses followed intention-to-treat, per-protocol, or another principle. It also does not report how missing diary entries or other incomplete endpoint measurements were handled. This matters because an endpoint based on days over a period depends on which observations are available and how incomplete periods are treated. In general, complete-case analysis, imputation, and likelihood-based approaches can rely on different assumptions; none should be attributed to this study without documentation.

There is also no reported accounting of participants who discontinued, the amount of missing endpoint data, or reasons for missingness. The registry’s stated enrollment and safety denominators do not by themselves reveal how many participants contributed to the primary efficacy analysis. These details are not reported in the registry record.

As a result, the outcome list should be treated as a description of planned or recorded measures, not evidence that each was analyzed under a known statistical procedure. The posted record does not allow readers to judge how multiplicity, incomplete data, or analysis-population choices affected the primary or secondary findings.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: gastrectomy (6.7%), cholecystitis (6.7%).

The serious adverse event entries list 15 participants at risk in each group. The IONIS-PKKRx group has 0 participants with a serious adverse event, and the placebo group has 2. The record lists 0 deaths in each group. These are registry counts; they do not indicate whether events were considered related to study treatment, nor do they establish a causal comparison between groups.

The record also lists other adverse events affecting 15 participants in the IONIS-PKKRx group and 8 in the placebo group. These figures should be kept distinct from the serious adverse event counts. The registry lists gastrectomy and cholecystitis among the top serious terms, each at 6.7%, but does not identify an arm for these terms in the information. They should not be assigned to a group based on the totals.

In general, adverse-event counts describe events recorded during a study and are not, by themselves, proof of cause. Sparse counts can be especially difficult to interpret: absence of a recorded event does not prove absence of risk, while an event in a trial does not establish that treatment caused it. The record does not provide event narratives, timing, relatedness assessments, or a statistical safety comparison. These figures are therefore descriptive and should be read with those limitations.

12. What the Result Does, and Does Not, Mean

This trial record establishes that a randomized, double-blind, placebo-controlled phase 2 study evaluated IONIS-PKKRx for preventive treatment of chronic migraine. It identifies migraine days as the primary endpoint and describes comparison of baseline with the final month of a 4-month treatment period. It also provides selected safety counts. These details explain what the study set out to examine and what is recorded in the registry.

The record does not provide a single numerical primary efficacy comparison, an effect estimate, confidence interval, or test result in the information. It therefore does not show how large a difference in migraine days was observed or how precisely any such difference was estimated. The outcome description alone cannot establish the direction or magnitude of a result. The registry record also does not report sufficient analysis details to assess the primary result across its several categories or time points.

The serious and other adverse-event figures are counts, not causal findings. In general, randomized assignment strengthens the basis for comparing groups, but interpretation also depends on complete follow-up, analysis choices, outcome ascertainment, and the precision of estimates. Details needed to assess those features are not reported in the registry record.

The study’s enrollment and its phase describe the scope of the trial, not the strength or certainty of an efficacy conclusion. The planning illustrations on the page are not observed power and should not be mistaken for evidence that the study detected or failed to detect a treatment effect. Any conclusion about benefit or harm would require results and analysis details beyond what is reported. This page interprets the posted record; it does not offer medical advice or a treatment recommendation.

13. Why This Trial Matters Statistically

This study is statistically interesting because it combines a randomized placebo comparison with a continuous endpoint based on migraine days. That design makes the intended contrast understandable: compare the endpoint between assigned groups over the stated treatment period rather than treating a change within one group as the whole answer. The registry record also illustrates why an endpoint definition and a numerical result are different things.

The primary outcome is described in terms of baseline and the final month, but the record indicates several categories or time points and does not reduce them to one comparison. Without a reported estimate and uncertainty, readers cannot determine the size or precision of the primary contrast. This is a practical lesson in trial reporting: a clear endpoint description is necessary, but it does not substitute for a transparent analysis result.

The study also highlights the importance of reporting analysis choices. Repeated measurements, missing observations, analysis populations, and multiplicity can affect how results should be interpreted. The registry record does not report these details. Their absence does not show that the study lacked appropriate methods; it means readers cannot evaluate those methods from this record.

Finally, the safety entries show why descriptive counts need context. Counts can be presented plainly, but they do not identify causation and may be imprecise in a small study. A planning illustration can help explore assumptions about future study sizes, but it cannot replace an observed effect estimate or the original design rationale. These distinctions are useful when reading trial registries across clinical areas.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation for interpretation is that the registry record does not report a single primary efficacy comparison. It gives the endpoint description and indicates that the primary outcome spans several categories or time points, but no group means, standard errors, effect estimate, confidence interval, or test result are available. Consequently, the size and precision of the primary result cannot be assessed from this record.

Important design and analysis details are also absent. The registry record does not report the randomization procedure, allocation concealment, which parties were masked, the analysis population, the statistical model, covariate adjustment, or handling of missing endpoint data. It does not report interim analyses, multiplicity procedures, or a statistical analysis plan. These omissions limit assessment of how the stated design was implemented and how the endpoint was analyzed; they are not evidence that a particular procedure was or was not used.

The record lists enrollment of 30 and gives safety denominators of 15 at risk in each arm, but does not provide baseline characteristics or the number contributing data to each efficacy analysis. It also does not provide event narratives, timing, relatedness, or arm attribution for the listed serious event terms in the information. This constrains interpretation of both efficacy and safety.

Finally, the planning illustrations are not the trial’s reported design justification or observed power. The registry record does not state how its original sample size was chosen. The trial’s phase and enrollment describe its scope, but do not by themselves establish the generalizability or precision of its findings.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine — NCT03108469.
• Registry record last updated 2020-02-12; status last verified 2020-02.
• Results first posted 2020-02-05.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry describes a completed phase 2 randomized, double-blind, placebo-controlled parallel-group study of IONIS-PKKRx (ISIS 546254) for chronic migraine. Enrollment was 30. Both groups were assigned weekly subcutaneous injections containing 1.00 mL (200mg) for weeks 1-16.

The primary endpoint was mean migraine days, comparing baseline with the treatment period up to 16 weeks; the description specifies the final month of the 4-month treatment period. The registry record does not provide a single primary comparison estimate or its uncertainty in the information. It lists secondary measures covering headache symptoms, medication use, quality of life, and global impressions.

Safety entries list 15 participants at risk in each group, with serious adverse events affecting 0 in the IONIS-PKKRx group and 2 in the placebo group, and no deaths in either group. These counts are descriptive. Analysis details, missing-data methods, multiplicity procedures, and the original sample-size rationale are not reported in the registry record.